Loading
Breast Cancer Treatment Studies / Ferroptosis and Cancer Prognosis · Journal article
Frontiers in Immunology · September 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review proposing a precision immunotherapy framework for triple-negative breast cancer, integrating evidence on molecular subgroups, biomarkers (PD-L1, tumor-infiltrating lymphocytes), and emerging tools. The authors acknowledge that checkpoint blockade plus chemotherapy is now standard for high-risk early-stage and PD-L1-positive metastatic TNBC, but note that benefit varies and resistance mechanisms limit durability, positioning multi-modal biomarker integration and emerging technologies as essential to optimize patient selection.
Journal article. Patients with triple-negative breast cancer (early-stage high-risk and metastatic disease).
Immune checkpoint blockade plus chemotherapy is now standard for high-risk early-stage TNBC and PD-L1-positive metastatic disease. Benefit varies by disease setting, assay, and immune phenotype. Biomarkers such as PD-L1 and tumor-infiltrating lymphocytes provide useful but incomplete guidance due to methodological differences and spatiotemporal heterogeneity.
A precision immunotherapy framework integrating TNBC molecular subgroups, validated biomarker models, rational combinations, and emerging tools is proposed to improve response durability while reducing unnecessary toxicity.
Clinicians should recognize that current PD-L1 and TIL-based biomarkers provide incomplete guidance for immunotherapy selection in TNBC; the proposed framework suggests that integrated molecular profiling, dynamic biomarkers, and emerging technologies may better identify patients who will benefit from checkpoint blockade versus those requiring intensified combinations or alternative strategies.
A comprehensive review integrating evidence from trials and biomarker studies to propose a precision immunotherapy framework for TNBC, addressing current standards and unresolved clinical challenges.
Clinicians should recognize that current PD-L1 and TIL-based biomarkers provide incomplete guidance for immunotherapy selection in TNBC; the proposed framework suggests that integrated molecular profiling, dynamic biomarkers, and emerging technologies may better identify patients who will benefit from checkpoint blockade versus those requiring intensified combinations or alternative strategies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer is an aggressive, biologically heterogeneous subtype with limited targeted therapies. Immunotherapy improves outcomes in selected patients, but durable benefit is limited by inter- and intratumoral heterogeneity, imperfect biomarkers, and primary or acquired resistance. This review integrates evidence from major positive and negative trials, molecular subgroup studies, predictive biomarkers, and tumor immune microenvironment research to assess current standards and unresolved challenges. Immune checkpoint blockade plus chemotherapy is now standard for high-risk early-stage TNBC and PD-L1-positive metastatic disease, although benefit varies by disease setting, assay, and immune phenotype. Biomarkers such as PD-L1 and tumor-infiltrating lymphocytes provide useful but incomplete guidance because of methodological differences, spatiotemporal heterogeneity, and treatment-induced changes. The central clinical challenge is to identify which patients require intensified immune-based combinations and which are unlikely to benefit from checkpoint blockade alone. We propose a precision immunotherapy framework that integrates TNBC molecular subgroups, validated and dynamic biomarker models, rational combinations, resistance mechanisms, and emerging tools, including single-cell sequencing, spatial transcriptomics, multi-omics, and AI-assisted stratification. This strategy may improve response durability while reducing unnecessary toxicity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.